Autologous BCMA/TACI-targeted CAR T Cells AUTO2 - CISMeF
Autologous BCMA/TACI-targeted CAR T Cells AUTO2NCIt concept
Preferred Label : Autologous BCMA/TACI-targeted CAR T Cells AUTO2;
NCIt synonyms : Autologous CAR T Product AUTO2; Autologous APRIL CAR T Cells; APRIL CAR T Cells Targeting BCMA and TACI; APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI;
NCIt definition : A preparation of autologous T-lymphocytes that are genetically engineered to contain
a dual-targeted chimeric antigen receptor (CAR), which includes the natural protein
a proliferation-inducing ligand (APRIL; TNFSF13), that targets the tumor-associated
antigens (TAAs) B-cell maturation antigen (BCMA; TNFRSF17) and transmembrane activator
and calcium modulator and cyclophilin ligand interactor (TACI; TNFRSF13B), with potential
immunomodulating and antineoplastic activities. Upon administration, the autologous
BCMA/TACI-targeted CAR T-cells AUTO2 bind to BCMA and TACI expressed on tumor cells
and induce selective cytotoxicity in those cells. In addition, AUTO2 carries the universal
RQR8 safety off switch, which allows selective removal of the T-cells through both
complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity
(ADCC) following administration of rituximab if unacceptable side-effects occur.;